-
公开(公告)号:US20160168223A1
公开(公告)日:2016-06-16
申请号:US15004281
申请日:2016-01-22
申请人: Amgen Inc.
发明人: Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
IPC分类号: C07K14/50
CPC分类号: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
摘要翻译: 本发明提供编码FGF21突变体多肽,FGF21突变体多肽,包含FGF21突变体多肽的药物组合物的核酸分子,以及使用此类核酸,多肽或药物组合物治疗代谢紊乱的方法。
-
公开(公告)号:US20190023757A1
公开(公告)日:2019-01-24
申请号:US15996232
申请日:2018-06-01
申请人: AMGEN INC.
发明人: Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
摘要: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号:US10011642B2
公开(公告)日:2018-07-03
申请号:US15004281
申请日:2016-01-22
申请人: Amgen Inc.
发明人: Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
-
4.FGF21 mutants comprising a mutation at position 98, 171 and/or 180 有权
标题翻译: 包含位置98,171和/或180处的突变的FGF21突变体公开(公告)号:US09493530B2
公开(公告)日:2016-11-15
申请号:US14167662
申请日:2014-01-29
申请人: AMGEN INC.
发明人: Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号: C07K14/50 , A61K38/00 , C07K2319/30
摘要: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.
摘要翻译: 本发明提供编码FGF21突变体多肽,FGF21突变体多肽,包含FGF21突变体多肽的药物组合物的核酸分子,以及使用此类核酸,多肽或药物组合物治疗代谢紊乱的方法。 在一些实施方案中,FGF21突变体多肽包含位置98,171和/或180处的取代。
-
公开(公告)号:US20240076333A1
公开(公告)日:2024-03-07
申请号:US18499499
申请日:2023-11-01
申请人: Amgen Inc.
发明人: Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , JIng Xu
CPC分类号: C07K14/50 , A61K38/1825 , A61K2039/505
摘要: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号:US09273106B2
公开(公告)日:2016-03-01
申请号:US14134482
申请日:2013-12-19
申请人: Amgen Inc.
发明人: Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要: The invention provides FGF21 mutant polypeptides with reduced proteolysis and aggregation, pharmaceutical compositions comprising the same.
摘要翻译: 本发明提供具有降低的蛋白水解和聚集的FGF21突变体多肽,其包含其的药物组合物。
-
公开(公告)号:US11072640B2
公开(公告)日:2021-07-27
申请号:US15996232
申请日:2018-06-01
申请人: AMGEN INC.
发明人: Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
摘要: The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
-
公开(公告)号:US20140243503A1
公开(公告)日:2014-08-28
申请号:US14134482
申请日:2013-12-19
申请人: Amgen Inc.
发明人: Edward John Belouski , Murielle Marie Ellison , Agnes Eav Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号:US11840558B2
公开(公告)日:2023-12-12
申请号:US17357444
申请日:2021-06-24
申请人: AMGEN INC.
发明人: Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号: C07K14/05 , A61K38/1825 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号:US20210317176A1
公开(公告)日:2021-10-14
申请号:US17357444
申请日:2021-06-24
申请人: AMGEN INC.
发明人: Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
摘要: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
-
-
-
-
-
-
-
-